Novo Nordisk AS (LTS:0QIU) Beginning Cash Position : kr15,655 Mil (As of Mar. 2025)

View and export this data going back to 2009. Start your Free Trial

What is Novo Nordisk AS Beginning Cash Position?

Novo Nordisk AS's Beginning Cash Position for the quarter that ended in Mar. 2025 was kr15,655 Mil.

Novo Nordisk AS's quarterly Beginning Cash Position increased from Sep. 2024 (kr52,821 Mil) to Dec. 2024 (kr57,018 Mil) but then declined from Dec. 2024 (kr57,018 Mil) to Mar. 2025 (kr15,655 Mil).

Novo Nordisk AS's annual Beginning Cash Position increased from Dec. 2022 (kr10,719 Mil) to Dec. 2023 (kr12,653 Mil) and increased from Dec. 2023 (kr12,653 Mil) to Dec. 2024 (kr14,392 Mil).

Novo Nordisk AS Beginning Cash Position Historical Data

The historical data trend for Novo Nordisk AS's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Beginning Cash Position Chart

Novo Nordisk AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Beginning Cash Position

Get a 7-Day Free Trial

15,411.00

12,226.00

10,719.00

12,653.00

14,392.00

Novo Nordisk AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Beginning Cash Position	Get a 7-Day Free Trial															14,392.00	6,324.00	52,821.00	57,018.00	15,655.00

Novo Nordisk AS Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Novo Nordisk AS Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (LTS:0QIU) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico 0TDD:UK NOVOBc:UK NOVO B:Denmark NOV:Germany NVON:Canada N1VO34:Brazil NOV:Bulgaria NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, 2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk AS Headlines

No Headlines